Hal M. Hoffman
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (5)
Year:
2026
Year:
2026
Year:
2025
The commitment of hematopoietic stem cells (HSC) to myeloid, erythroid, and lymphoid lineages is influenced by microenvironmental cues, and governed by cell-intrinsic and epigenetic characteristics that are unique to the HSC population. To investigate the nature of lineage commitment bias in human HSC, mitochondrial single cell (sc) ATAC-Sequencing (mt-scATAC-Seq) was used to identify somatic mutations in mitochondrial DNA to act as natural genetic barcodes for tracking the ex vivo differentiation potential of HSC to mature cells. Clonal lineages of human CD34 + cells and their mature progeny were normally distributed across the hematopoietic lineage tree without evidence of significant skewing. To investigate commitment bias in vivo , mice were transplanted with limited numbers of long-term HSC (LT-HSC). Variation in the ratio of myeloid and lymphoid cells between donors, although suggestive of a skewed output, was not altered by increasing numbers of LT-HSC. These data suggest that the variation in myeloid and lymphoid engraftment is a stochastic process influenced by the irradiated recipient niche and not a cell-intrinsic lineage bias of LT-HSC.
Year:
2024
Summary From studies of individual families to global collaborative efforts, the NLRP3 inflammasome is now recognized to be a key regulator of innate immunity. Activated by a panoply of pathogen‐associated and endogenous triggers, NLRP3 serves as an intracellular sensor that drives carefully coordinated assembly of the inflammasome, and downstream inflammation mediated by IL‐1 and IL‐18. Initially discovered as the cause of the autoinflammatory spectrum of cryopyrin‐associated periodic syndrome (CAPS), NLRP3 is now also known to play a role in more common diseases including cardiovascular disease, gout, and liver disease. We have seen cohesion in results from clinical studies in CAPS patients, ex vivo studies of human cells and murine cells, and in vivo murine models leading to our understanding of the downstream pathways, cytokine secretion, and cell death pathways that has solidified the role of autoinflammation in the pathogenesis of human disease. Recent advances in our understanding of the structure of the inflammasome have provided ways for us to visualize normal and mutant protein function and pharmacologic inhibition. The subsequent development of targeted therapies successfully used in the treatment of patients with CAPS completes the bench to bedside translational loop which has defined the study of this unique protein.
Year:
2023
Collaborators (5)
Nathan Lewis
Eminent Scholar and Professor
University of California, San Diego
Tomofumi Numata
Associate professor (Special Appointment)
Hiroshima University
Naotomo Kambe
准教授 / Associate Professor
Kyoto University
David Gonzalez
University of California, San Diego
Ben Croker
Professor
University of California, San Diego
Make your next move.
Prepare your application
Review drafts before you send them.